Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

August 24, 2022

Study Completion Date

August 24, 2022

Conditions

Type 2 Diabetes

Interventions

DRUG

HRS9531

Administered SC once

OTHER

placebo

Administered SC once

DRUG

HRS9531

Administered SC for multiple dose

OTHER

placebo

Administered SC for multiple dose

Trial Locations (1)

Jinan Central Hospital, Jinan

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT05152277 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy Subjects | Biotech Hunter | Biotech Hunter